Ironshore Pharmaceuticals & Development, Inc.

Ironshore Pharmaceuticals & Development, Inc., is leveraging its proprietary technology, DELEXIS®, to optimize the delivery of previously approved drug products. Ironshore is dedicated to developing novel formulations to treat ADHD and address prevalent unmet needs in the treatment of the disease along with innovative nighttime dosing technology used to treat ADHD and are being developed to address a prevalent unmet medical need in the treatment of the disease– inadequate symptom control during the morning routine. Intended for nighttime dosing, DELEXIS® is designed to provide a consistent delay in the initial release of the active drug, followed by a period of extended release; with the objective of providing symptom control upon wakening and throughout the day. Ironshore Pharmaceuticals & Development, Inc. is a wholly owned subsidiary of Highland Therapeutics, Inc.